BetterScholar BetterScholar

A. Stalenhoef

European Heart Journal, Journal of Lipid Research, New England Journal of Medicine, Arteriosclerosis and Thrombosis A Journal of Vascular Biology, Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir, The Lancet Diabetes and Endocrinology, Journal of Internal Medicine, Circulation, Nature Network Boston Show more
13
Role
Title
Level Year L/R
🐜 Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease
28 auth. B. Nordestgaard, M. Chapman, S. Humphries, H. Ginsberg, L. Masana, O. Descamps, O. Wiklund, R. Hegele, F. Raal, J. Defesche, A. Wiegman, R. Santos, G. Watts, K. Parhofer, G. Hovingh, ... P. Kovanen, C. Boileau, M. Averna, J. Borén, E. Bruckert, A. Catapano, J. Kuivenhoven, P. Pajukanta, K. Ray, A. Stalenhoef, E. Stroes, M. Taskinen, A. Tybjærg‐Hansen 		10 2013
10
🐜
🐜 Simvastatin with or without ezetimibe in familial hypercholesterolemia.
15 auth. J. Kastelein, F. Akdim, E. Stroes, A. Zwinderman, M. Bots, A. Stalenhoef, F. Visseren, E. Sijbrands, M. Trip, E. Stein, ... D. Gaudet, R. Duivenvoorden, E. Veltri, A. Marais, E. de Groot 		10 2008
10
🐜
🐢 Clinical Practice Guideline: Evaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice Guideline
7 auth. L. Berglund, J. Brunzell, A. Goldberg, I. Goldberg, F. Sacks, M. Murad, ... A. Stalenhoef 		9 2012
9
🐢
🐢 Enhanced susceptibility to in vitro oxidation of the dense low density lipoprotein subfraction in healthy subjects.
J. Graaf, H. Hak-Lemmers, M. Hectors, P. Demacker, J. C. Hendriks, A. Stalenhoef 		9 1991
9
🐢
🐜 Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society
31 auth. M. Cuchel, E. Bruckert, H. Ginsberg, F. Raal, R. Santos, R. Hegele, J. Kuivenhoven, B. Nordestgaard, O. Descamps, E. Steinhagen-Thiessen, A. Tybjærg‐Hansen, G. Watts, M. Averna, C. Boileau, J. Borén, ... A. Catapano, J. Defesche, G. Hovingh, S. Humphries, P. Kovanen, L. Masana, P. Pajukanta, K. Parhofer, K. Ray, A. Stalenhoef, E. Stroes, M. Taskinen, A. Wiegman, O. Wiklund, M. Chapman, M. Cuchel 		9 2014
9
🐜
🐜 Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment
32 auth. A. Wiegman, S. Gidding, G. Watts, M. Chapman, H. Ginsberg, M. Cuchel, L. Ose, M. Averna, C. Boileau, J. Borén, E. Bruckert, A. Catapano, J. Defesche, O. Descamps, R. Hegele, ... G. Hovingh, S. Humphries, P. Kovanen, J. Kuivenhoven, L. Masana, B. Nordestgaard, P. Pajukanta, K. Parhofer, F. Raal, K. Ray, R. Santos, A. Stalenhoef, Elisabeth Steinhagen- Thiessen, E. Stroes, M. Taskinen, A. Tybjærg‐Hansen, O. Wiklund 		9 2015
9
🐜
🐢 The role of TNF-alpha in chronic inflammatory conditions, intermediary metabolism, and cardiovascular risk.
C. Popa, M. Netea, P. V. van Riel, J. V. D. van der Meer, A. Stalenhoef 		9 2007
9
🐢
🐜 The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management.
25 auth. R. Hegele, H. Ginsberg, M. Chapman, B. Nordestgaard, J. Kuivenhoven, M. Averna, J. Borén, E. Bruckert, A. Catapano, O. Descamps, G. Hovingh, S. Humphries, P. Kovanen, L. Masana, P. Pajukanta, ... K. Parhofer, F. Raal, K. Ray, R. D. Santos, A. Stalenhoef, E. Stroes, M. Taskinen, A. Tybjærg‐Hansen, G. Watts, O. Wiklund 		8 2014
8
🐜
🐜 Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty‐person/ten‐country panel
30 auth. P. Barter, C. Ballantyne, R. Carmena, M. Cabezas, M. Chapman, P. Couture, J. Graaf, P. Durrington, O. Faergeman, Jiri J. Frohlich, C. Furberg, C. Gagné, S. Haffner, S. Humphries, I. Jungner, ... R. Krauss, P. Kwiterovich, S. Marcovina, C. Packard, T. Pearson, K. S. Reddy, R. Rosenson, N. Sarrafzadegan, A. Sniderman, A. Stalenhoef, E. Stein, P. Talmud, A. Tonkin, G. Walldius, K. Williams 		8 2006
8
🐜
🐜 Efficacy and Safety of a Novel Cholesteryl Ester Transfer Protein Inhibitor, JTT-705, in Humans: A Randomized Phase II Dose-Response Study
8 auth. G. J. de Grooth, J. Kuivenhoven, A. Stalenhoef, J. de Graaf, A. Zwinderman, J. Posma, ... A. van Tol, J. Kastelein 		8 2002
8
🐜
🐜 Deficiency of interleukin-18 in mice leads to hyperphagia, obesity and insulin resistance
18 auth. M. Netea, L. Joosten, E. Lewis, D. Jensen, P. Voshol, B. Kullberg, C. Tack, H. Krieken, Soohyun Kim, A. Stalenhoef, ... F. Loo, Ineke C Verschueren, L. Pulawa, S. Akira, R. Eckel, C. Dinarello, W. B. Berg, J. Meer 		8 2006
8
🐜
🐜 Homozygous autosomal dominant hypercholesterolaemia in the Netherlands: prevalence, genotype-phenotype relationship, and clinical outcome.
13 auth. B. Sjouke, D. Kusters, I. Kindt, J. Besseling, J. Defesche, E. Sijbrands, J. E. Roeters van Lennep, A. Stalenhoef, A. Wiegman, J. de Graaf, ... S. Fouchier, J. Kastelein, G. Hovingh 		8 2015
8
🐜
🐜 Relationship between stearoyl-CoA desaturase activity and plasma triglycerides in human and mouse hypertriglyceridemia Published, JLR Papers in Press, August 16, 2002. DOI 10.1194/jlr.M200189-JLR200
11 auth. A. Attie, R. Krauss, M. Gray-Keller, A. Brownlie, M. Miyazaki, J. Kastelein, ... A. Lusis, A. Stalenhoef, J. Stoehr, M. Hayden, J. Ntambi 		8 2002
8
🐜